Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study. Prostate-specific antigen (PSA) ...
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma Factors correlated with ...
2don MSN
Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, study finds
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to ...
The most common screening test for prostate cancer so often returns a false positive result that it's no longer recommended for men older than 70, and it's offered as a personal choice for younger men ...
Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer Following investigational new ...
At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...
− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results